N
Newton | Neurolens
Designs prescription lenses that add a contoured prism to bring the eyes into alignment
About Newton | Neurolens
Newton (formerly Neurolens, originally EyeBrain Medical) is an eyecare-technology company founded in 2012 that develops therapeutic prescription lenses addressing vision misalignment — the underlying cause of symptoms such as headaches, neck pain, eye strain and motion sickness. Its flagship NeuroLens system pairs the N3 diagnostic device, which uses VR and eye tracking to measure binocular misalignment, with the first prescription lenses to feature patented Contoured Prism™ technology; the company reports that 90% of patients experience symptom relief. In September 2025 the company rebranded from Neurolens to Newton, and it has since expanded its portfolio with Sequel, an everyday lens built on Convergence Boost™ technology, and acquired Founders Optical Lab in late 2025. Newton has raised over $170 million to date — including a $67 million round in 2022 led by MVM Life Science Partners with KKR, Marshall Wace and Bluestem Capital, and a $45 million growth investment from Trinity Capital in 2023 — and distributes through independent eye care providers across North America. Led by CEO Davis Corley, the company is headquartered in Coppell, Texas.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 139
- Open positions
- None listed
- Dealroom signal
- 68.6/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Neurology, Optical Technology, Hard Tech
- Business model
- Manufacturing, Marketplace & ecommerce
- Client focus
- B2B, B2C
- Investment activity
- 1 company, latest Nov 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Dec 2023 | $45M | — | Trinity Capital | ↗ |
| LATE VCOther financing | Sep 2022 | $67M | $268M | Bluestem Capital · MVM Life Science Partners · KKR · Marshall Wace | ↗ |
Growth signals
Latest recorded traffic for Newton | Neurolens is 14K monthly website visits, down 6.7% over the last three months. Newton | Neurolens's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Newton | Neurolens in the Coppell ecosystem
The Newton | Neurolens office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
MVM Life Science Partners
Bluestem Capital
KKR
Marshall Wace
Trinity Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Newton | Neurolens on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Newton | Neurolens’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









